About this trial
The goal of this clinical study is to evaluate the safety and preliminary efficacy of an investigational umbilical cord blood-derived stem cell and exosome infusion in adults with chronic lower back pain associated with degenerative spine disease. The primary questions this study aims to answer are whether the investigational infusion is safe and well tolerated and whether treatment may reduce pain and improve physical function and quality of life. Researchers will compare the investigational infusion to a placebo (saline solution) to evaluate potential treatment effects in participants with chronic mechanical lower back pain. Participants will receive either the investigational infusion or placebo intravenously during a study visit, complete pain, disability, and quality-of-life assessments, undergo magnetic resonance imaging (MRI) and laboratory testing, and attend follow-up evaluations over a 6-month period. Participants initially assigned to placebo may later receive the investigational treatment during an open-label crossover phase of the study.
Eligibility criteria
Qualifiers
Age 18-85 years
Chronic lower back pain ≥3 months
Baseline VAS-Average ≥4/10
Able to comply with study visits and procedures
Disqualifiers
Pregnancy or breastfeeding
Prisoners or decisionally impaired adults
Active malignancy (except non-melanoma skin cancer)
Immunodeficiency or active systemic infection
Trial design
Treatments tested in this trial
- Umbilical Cord Blood-Derived Stem Cells and Exosomes
- Placebo IV